Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Ulcerative Colitis · Multiple Myeloma

AbbVie Deutschland GmbH

AbbVie Deutschland GmbH & Co. KG

AbbVie Deutschland GmbH trial registry — 102 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Wiesbaden, DE HQ
2018 Founded
101 Employees
EMA registrant Type
Company details
Status
Public
HQ
Wiesbaden, DE
Founded
2018
Employees
101
Programs
102
Drugs
119
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

AbbVie Deutschland GmbH clinical trials

Registry index of 102 ClinicalTrials.gov studies linked to AbbVie Deutschland GmbH programs — each row shows trial ID, program name, phase, status, and indication.

AbbVie Deutschland GmbH trial registry — 102 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for AbbVie Deutschland GmbH.

  1. M24-209 — Phase 2

    Clinical update

  2. M24-427 — Phase 1

    Clinical update

  3. M23-422 — Phase 2

    Clinical update

  4. TNB383B.0001/M22-466 — Phase 1

    Clinical update

  5. RGX-314-3101/M23-409 — Phase 3

    Clinical update

  6. PCYC-1146-IM — Phase 2

    Clinical update

  7. M24-147 — Phase 2

    Clinical update

  8. M24-052 — Phase 3

    Clinical update

Trial registry

102 studies
  19. 2023-505479-56-00

    M22-716

    Phase 1 active other

    Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

    CTIS ↗
  26. 2023-505773-32-00

    M23-721

    Phase 3 active small_molecule

    Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer, Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    CTIS ↗
  36. 2023-506842-22-00

    IMGN151-1001

    Phase 2 active small_molecule

    Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC), recurrent cervical cancer

    CTIS ↗
  49. 2023-507329-40-00

    Ibrutinib

    Approved active small_molecule

    1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma

    CTIS ↗
  55. 2023-509335-60-00

    M21-404

    Phase 1 active other

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    CTIS ↗
  72. 2024-513625-23-00

    M16-573

    Phase 1 active other

    Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.